Coming Soon – October 2019 MARKET OUTLOOK Rituximab-based...
Coming Soon – October 2019 MARKET OUTLOOK Rituximab-based chemoimmunotherapy regimens (e.g...
MARKET OUTLOOK Rheumatoid arthritis (RA) patients refractory to one or more...
MARKET OUTLOOK Rheumatoid arthritis (RA) patients refractory to one or more TNF-&alp......
MARKET OUTLOOK Dyslipidemia is an important modifiable risk factor for CV...
MARKET OUTLOOK Dyslipidemia is an important modifiable risk factor for CV disease and is primarily managed with statin therapy. Based......
MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy...
MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy despite the availability of several treatment options. Resistance to therapy is the primary trea......
Childhood absence epilepsy (CAE) is characterized by frequent and brief...
Childhood absence epilepsy (CAE) is characterized by frequent and brief absence seizures in children aged 4-12 and is diagnosed in approximately 10......
MARKET OUTLOOK Treatment of moderate to severe Crohn’s disease (CD)...
MARKET OUTLOOK Treatment of moderate to severe Crohn’s disease (CD) typically begins with safe, albeit often less-efficacious...
MARKET OUTLOOK Tumor necrosis factor-alpha (TNF-α) inhibitors (AbbVie’s...
MARKET OUTLOOK Tumor necrosis factor-alpha (TNF-α) inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen&...
MARKET OUTLOOK With a drug-treated population of more than 4 million people...
MARKET OUTLOOK With a drug-treated population of more than 4 million people in the United States and EU5, th......
Several antipsychotic therapies are available for the treatment of...
Several antipsychotic therapies are available for the treatment of schizophrenia and primarily control the positive symptoms of the disease. However, given that a sizable portion of schizophreni......
MARKET OUTLOOK The moderate to severe ulcerative colitis (UC) therapy market...
MARKET OUTLOOK The moderate to severe ulcerative colitis (UC) therapy market still offers substantial opportunity for companies that can address the remaining unmet need......
Fibromyalgia is a chronic condition characterized by pain and tenderness. The...
Fibromyalgia is a chronic condition characterized by pain and tenderness. The primary goal of treatment is to reduce pain, and there are multiple well-established treatment options available, man......
MARKET OUTLOOK Roche/Genentech achieved a clinical and regulatory milestone...
MARKET OUTLOOK Roche/Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (...
MARKET OUTLOOK Obesity is arguably the most pressing public health issue in...
MARKET OUTLOOK Obesity is arguably the most pressing public health issue in the United States with its chronic progression that is associated with both type 2 diabe...
Coming Soon – September 2019 Peripheral arterial disease (PAD) is a...
Coming Soon – September 2019 Peripheral arterial disease (PAD) is a complex manifestation of underlying atherosclerotic disease and is a severely undertreated...
Coming Soon - September 2019 Physicians treating renal anemia are limited...
Coming Soon - September 2019 Physicians treating renal anemia are limited to iron supplements and erythropoietin-stimulating agents (ESAs), which, although effectiv...
Coming Soon – November 2019 Despite heart failure with preserved ejection...
Coming Soon – November 2019 Despite heart failure with preserved ejection fraction (HFpEF) accounting for approximately half of all chronic heart failure (CHF...
Coming Soon – April 2019 Insomnia is a highly prevalent sleep disorder...
Coming Soon – April 2019 Insomnia is a highly prevalent sleep disorder characterized by daytime dysfunction resulting from sleep problems. The treatment of insomnia is...
Coming Soon – May 2019 DED is one of the most common ocular conditions and...
Coming Soon – May 2019 DED is one of the most common ocular conditions and is characterized by insufficient tears to lubricate...
Coming Soon – May 2019 The management of pediatric patients with moderate...
Coming Soon – May 2019 The management of pediatric patients with moderate to severe atopic dermatitis (AD) is poised for a transformation. Sanofi/Regeneron’...
As the term implies, levodopa-induced dyskinesia (LID) is a complication of...
As the term implies, levodopa-induced dyskinesia (LID) is a complication of chronic use of levodopa, the goldstandard of Parkinson’s disease...
